Pfizer Pat. Law

RECEIVED **CENTRAL FAX CENTER**

02:00:02 p.m.

09-19-2007

5 /6

Customer No. 25533

SEP 1 9 2007

Confirmation No. 6396

PTO/SB/26 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) PC27788
In re Application of: Daniel P. Becker et al.	
Application No.: 10/722,104	
Filed November 25, 2003	
For: HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE	AS PROTEASE INHIBITORS
except as provided below, the terminal part of the statutory term of any patent granted on the instant :	prior patent is defined in 35 U.S.C. 154 bwner hereby agrees that any patent so
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by	prior patent, "as the term of sald prior
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, etc.), the undersigned is empowered to act on behalf of the business/organization.	, government agency,
I hereby declare that all statements made herein of my own knowledge are true and that all belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United Statements may jeopardize the validity of the application or any patent issued thereon.	willful false statements and the like se
2. The undersigned is an attorney or agent of record. Reg. No. 28,075	
A 1	
John H. Ergelann	SEPT. 11, 2007
Signature	Da(e
John H. Engelmann	
Typed or printed name	
•	269-833-2532
- -	Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information be included on this form. Provide credit card information and authorization of	tion should not in PTO-2038,
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (%) (69)/20/20/20/20/20/20/20/20/20/20/20/20/20/	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.